Saint-Gobain Life Sciences Introduces Highly Efficient Cell Culture Bags for T Cell Expansion
24.2.2021 18:00:00 EET | Business Wire | Press release
Saint-Gobain Life Sciences, an industry leader in material science-based solutions for cell and gene therapy manufacturing, today launched a new cell culture bag designed specifically for T cell derived therapies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005014/en/
VueLife® "HP" Series Bag cell culture testing in Saint-Gobain Life Sciences Laboratory. (Photo: Business Wire)
T cell based therapies are revolutionizing the approach to treating cancer. Harnessing the patient’s own immune system by isolating their T cells and engineering them to elicit an immune response is emerging as a preferred manufacturing practice. As the industry continues the advancement of these therapies, process efficiency becomes paramount to the success of delivering affordable therapies to patients.
Building upon the VueLife® family of fluorinated ethylene propylene (FEP) based cell culture bags, VueLife® “HP” (high permeability) incorporates an innovative, patented laminate film layer that allows increased CO2 and O2 exchange versus other monolayer bag designs, yet maintains the scalability and process flexibility offered by a closed bag system. The increased permeability associated with the “HP” laminate layer was specifically designed for culturing cells requiring higher rates of respiration, such as T cells.
“The development of this product was in direct response to the market need for a cost effective culture vessel that provides efficient cell expansion in a scalable, closed system,” said Benjamin Le Quere, General Manager for the Saint-Gobain Life Sciences Bioprocess Solutions business unit. “VueLife® “HP” is an exciting result of the marrying of our expertise in material science with our knowledge in cell culture.”
The entire family of VueLife® cell culture bags utilize a common FEP fluid-contact layer. FEP creates an ideal environment for cell growth due to its gas permeability and liquid impermeability, while being biologically and chemically inert.
ABOUT SAINT-GOBAIN LIFE SCIENCES
Dedicated to improving the quality of life, Saint-Gobain Life Sciences develops and manufactures high-performance components and integrated solutions that touch a broad range of patient care, from the development of new therapeutic cancer treatments to biopharmaceutical production, on through to intravenous therapies for drug delivery.
Along with material science expertise and collaborative design services, our focus on global quality and regulatory affairs allow us to be the trusted partner to organizations reaching every part of the globe. Combining our technical expertise, global manufacturing capabilities and research and development resources, Saint-Gobain Life Sciences is dedicated to meeting the evolving needs of bioprocess, medical and pharmaceutical customers around the world. Saint-Gobain Life Sciences is part of Compagnie de Saint-Gobain.
Compagnie de Saint-Gobain designs, manufactures and distributes materials and solutions which are key ingredients in the wellbeing of each of us and the future of all. They can be found everywhere in our living places and our daily life: in buildings, transportation, infrastructure and in many industrial applications. They provide comfort, performance and safety while addressing the challenges of sustainable construction, resource efficiency and climate change. Saint-Gobain operates in 70 countries with more than 180,000 employees worldwide. The Company had €42.6 billion in sales in 2019.
www.celltherapy.saint-gobain.com/products/cell-culture-processing-bags/vuelife-hp-series
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005014/en/
Contact information
Media Contact:
Katy Oroszi:
330-283-3536
Katy.Oroszi@saint-gobain.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sugar Taxes Under Scrutiny: New Competere Study Questions Health Outcomes and Warns of Unintended Consequences5.11.2026 13:00:00 EET | Press release
As governments debate sugar taxation and nutrition measures, a new policy paper asks a critical question: Do these interventions deliver lasting health improvements, for whom, and at what cost? Published by Competere with the support of the Association of Latin American Sugar Producers (UNALA), Understanding Sugar Beyond the Narrative – by Pietro Paganini – offers policymakers, journalists, and consumers an accessible guide to sugar’s role in health, sustainability, and the global economy. Combining scientific evidence with economic and policy analysis, the paper challenges common misconceptions and examines whether taxation, warning labels, and reformulation deliver measurable health benefits. While sugar taxes can influence prices, purchases, and product composition, evidence of lasting improvements in obesity, diabetes, and cardiovascular health remains limited. Intermediate outcomes should not be confused with demonstrated health benefits. Reviewed studies estimate reductions of 2.
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates5.11.2026 13:00:00 EET | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in patients, and now joined by our next-generation BCL2 inhibitor BEQALZI. We look forward to multiple catalysts in the coming months from one of the deepest pipelines in oncology, spanning hematology and solid tumors, accelerated by our differentiated capabilities in R&D, manufacturing, and commercialization.” (Amounts in thousands of U.S. dollars and unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2026 2025 % Change 2026 2025 % Change Net product revenues $ 1,855,057 $ 1,395,013 33 % $ 5,022,180 $
Klarna Goes Global With Anti-Scam Call Verification5.11.2026 12:52:00 EET | Press release
Klarna, the everyday finance network, today announced its popular in-app Call Status Detection tool is now live globally, giving consumers a reliable and simple way to check whether someone calling them is genuinely from Klarna. Call Status Detection has already helped thousands of consumers verify calls since it launched in the Nordics in September. The feature has now been rolled out globally, reflecting Klarna’s commitment to protecting its customers from fraud. Call Status Detection is quick and easy to use by design. If a customer takes a call from someone claiming to be Klarna, all they have to do is open the Klarna app and check the banner at the top of their screen — green means the call is verified and it is safe to continue, while amber means Klarna cannot verify the call and the customer should hang up. The feature builds on Klarna’s existing anti-fraud measures like the Klarna Inbox, which enables verification of written communication like emails, texts and letters, and aim
Prodalim Acquires South Africa’s Brenn-O-Kem, Expanding Its Global Circular Economy Platform with High-Value Grape-Based Specialty Ingredients5.11.2026 12:17:00 EET | Press release
Prodalim announced the acquisition of Brenn-O-Kem (BOK), a South African leader in upcycling winery by-products into high-value specialty ingredients for the wine, food and beverage, nutraceutical, agricultural and pharmaceutical industries. The acquisition strengthens Prodalim’s global circular economy platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103526127/en/ BOK transforms grape pomace and wine lees into a broad portfolio of natural, clean-label ingredients, including recycled aromatic alcohol for the wine and spirits industry; tartaric acid and derivatives for food, beverage and pharmaceutical applications; grape seed extracts for nutraceuticals; grape skin extracts for natural colors; grape seed oils and wine concentrates for culinary applications; and recycled compost for animal nutrition. Prodalim will acquire 93.25% of BOK for 37M USD. Founded in 1968, BOK operates three production sites in South Afric
SES Delivers Solid 9 Months & Q3 2026 Results and Reiterates Full-Year Outlook5.11.2026 11:22:00 EET | Press release
SES S.A. announces financial results for the nine and three months ended September 30, 2026. YTD 2026 Performance (€ million) YTD 2026 as reported (1) YTD 2025 as reported (1)(5) ∆ At constant FX (2) YTD 2025 like-for-like(3) ∆ At constant FX (2) Average €/$ FX rate 1.16 1.11 1.11 Revenue 2,472 1,743 +45.5% 2,628 -2.0% Adjusted EBITDA (4) 1,138 838 +40.0% 1,170 +1.4% 1) ‘Reported basis’ with Intelsat fully consolidated from July 17, 2025 2) ‘At constant FX’ refers to comparative figures restated at the current period FX rates to neutralize currency variations 3) ‘Like-for-like basis’ is as if Intelsat was fully consolidated from January 1, 2024 4) Excluding operating expenses/income recognized in relation to U.S. C-band repurposing, other income non-recurring, fair value movement on contingent value rights and other significant special items (disclosed separately) 5) 2025 has been restated to reflect Purchase Price Allocation (PPA) adjustments recorded in connection with the acquisitio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom